Last update 16 Jul 2025

NKT-5097

Overview

Basic Info

Drug Type
Proteolysis-targeting chimeras (PROTAC)
Synonyms
CDK2/4 selective dual degrader, NKT-5097
Target
CDK2 x CDK4
Action
degraders
Mechanism
CDK2 degraders(Cyclin-dependent kinase 2 degraders), CDK4 degraders(Cyclin-dependent kinase 4 degraders)
Therapeutic Areas
NeoplasmsEndocrinology and Metabolic DiseaseSkin and Musculoskeletal Diseases+ [1]
Active Indication
Advanced Malignant Solid NeoplasmEndometrial CarcinomaHER2-negative breast cancer+ [4]
Inactive Indication-
Originator Organization
NiKang Therapeutics, Inc.NiKang Therapeutics, Inc.
Active Organization
NiKang Therapeutics, Inc.NiKang Therapeutics, Inc.
Inactive Organization-
License Organization-
Drug Highest PhasePhase 1
First Approval Date-
Regulation-
Login to view timeline

Related

1
Clinical Trials associated with NKT-5097
NCT07029399
/ RecruitingPhase 1
A Phase 1, First-in-Human, Open-Label Study to Evaluate the Safety, Tolerability, PK, and Preliminary Anti-tumor Activity of the Novel Oral Selective CDK2/CDK4 Dual Degrader NKT5097 in Adults With Advanced/Metastatic Solid Tumors
100 Clinical Results associated with NKT-5097
Login to view more data
100 Translational Medicine associated with NKT-5097
Login to view more data
100 Patents (Medical) associated with NKT-5097
Login to view more data
100 Deals associated with NKT-5097
Login to view more data

R&D Status

10 top R&D records.
Login
to view more data
IndicationHighest PhaseCountry/LocationOrganizationDate
Advanced Malignant Solid NeoplasmPhase 1
United States
NiKang Therapeutics, Inc.NiKang Therapeutics, Inc.
30 Jun 2025
Endometrial CarcinomaPhase 1
United States
NiKang Therapeutics, Inc.NiKang Therapeutics, Inc.
30 Jun 2025
HER2-negative breast cancerPhase 1
United States
NiKang Therapeutics, Inc.NiKang Therapeutics, Inc.
30 Jun 2025
Hormone receptor positive breast cancerPhase 1
United States
NiKang Therapeutics, Inc.NiKang Therapeutics, Inc.
30 Jun 2025
Ovarian CancerPhase 1
United States
NiKang Therapeutics, Inc.NiKang Therapeutics, Inc.
30 Jun 2025
Triple Negative Breast CancerPhase 1
United States
NiKang Therapeutics, Inc.NiKang Therapeutics, Inc.
30 Jun 2025
Uterine CarcinosarcomaPhase 1
United States
NiKang Therapeutics, Inc.NiKang Therapeutics, Inc.
30 Jun 2025
Login to view more data

Clinical Result

Indication
Phase
Evaluation
View All Results
Study
Phase
PopulationAnalyzed EnrollmentGroupResultsEvaluationPublication Date

No Data

Login to view more data

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Core Patent

Boost your research with our Core Patent data.
login
or
view full example data
Boost your research with our Core Patent data.

Clinical Trial

Identify the latest clinical trials across global registries.
login
or
view full example data
Identify the latest clinical trials across global registries.

Approval

Accelerate your research with the latest regulatory approval information.
login
or
view full example data
Accelerate your research with the latest regulatory approval information.

Regulation

Understand key drug designations in just a few clicks with Synapse.
login
or
view full example data
Understand key drug designations in just a few clicks with Synapse.
AI Agents Built for Biopharma Breakthroughs
Accelerate discovery. Empower decisions. Transform outcomes.
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free